Lipid-Polimer Hibrit Nanopartiküller: Özellikleri, Hazırlama Yöntemleri ve Karakterizasyonlarına Güncel Bir Bakış
Farabi Tıp Dergisi, cilt.4, sa.3, ss.94-111, 2025 (Hakemli Dergi)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 4 Sayı: 3
- Basım Tarihi: 2025
- Doi Numarası: 10.59518/farabimedj.1735159
- Dergi Adı: Farabi Tıp Dergisi
- Sayfa Sayıları: ss.94-111
- Karadeniz Teknik Üniversitesi Adresli: Evet
Özet
Nano-sized drug delivery systems enhance treatment efficacy in many diseases, particularly cancer. Among these systems, there is intense interest in lipid-polymer hybrid nanoparticles (LPHNPs), which combine the advantages of lipid and polymer nanoparticles. This study aims to investigate the properties, preparation methods, and characterization of LPHNPs using Google Scholar, YÖK Thesis Center, ScienceDirect, PubMed, ResearchGate, ACS Publication, and Taylor & Francis Online as sources. The literature shows that LPHNPs with a core-shell structure have many advantages, including high stability, biocompatibility, bioavailability, and drug loading capacity, loading of both hydrophilic and hydrophobic drugs, controlled and sustained release, surface modification, and targeting. On the other hand, the inability to obtain a core-shell structure, scaling difficulties, and technical issues are disadvantages of LPHNPs. Preparation methods for LPHNPs, which affect many properties such as size, size distribution, and morphology, are divided into two main categories: the ‘two-step method’ and the ‘one-step method’. However, to overcome the disadvantages of these two methods, new techniques such as the ‘microfluidic nanoprecipitation method’, ‘multi-inlet vortex microreactor method’, and ‘one-step sonication method’ have been developed. Their efficacy and stability have been evaluated by determining their colloidal properties, drug loading capacities, morphologies, lipid shell thicknesses, release rates, efficacies, and toxicities through various in vitro and in vivo experiments. Although products in the form of liposomes or nanoparticles have been approved by health authorities, there are currently no products in phase trials or approved for LPHNPs, which are a relatively new system. However, the positive results obtained from various studies on LPHNPs are expected to reverse this situation in the near future.